{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T11:49:56Z","timestamp":1790423396943,"version":"4.1.0"},"reference-count":59,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T00:00:00Z","timestamp":1600992000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"SATT AxLR","award":["FR-2005\u2013138"],"award-info":[{"award-number":["FR-2005\u2013138"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,2,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Current therapies in Alzheimer\u2019s disease (AD), including Memantine, have proven to be only symptomatic but not curative or disease modifying. Fluoroethylnormemantine (FENM) is a structural analogue of Memantine, functionalized with a fluorine group that allowed its use as a positron emission tomography tracer. We here analyzed FENM neuroprotective potential in a pharmacological model of AD compared with Memantine.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Swiss mice were treated intracerebroventricularly with aggregated A\u03b2\u200a25\u201335 peptide and examined after 1 week in a battery of memory tests (spontaneous alternation, passive avoidance, object recognition, place learning in the water-maze, topographic memory in the Hamlet). Toxicity induced in the mouse hippocampus or cortex was analyzed biochemically or morphologically.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Both Memantine and FENM showed symptomatic anti-amnesic effects in A\u03b2\u200a25-35-treated mice. Interestingly, FENM was not amnesic when tested alone at 10 mg\/kg, contrarily to Memantine. Drugs injected once per day prevented A\u03b2\u200a25-35-induced memory deficits, oxidative stress (lipid peroxidation, cytochrome c release), inflammation (interleukin-6, tumor necrosis factor-\u03b1 increases; glial fibrillary acidic protein and Iba1 immunoreactivity in the hippocampus and cortex), and apoptosis and cell loss (Bcl-2\u2013associated X\/B-cell lymphoma 2 ratio; cell loss in the hippocampus CA1 area). However, FENM effects were more robust than observed with Memantine, with significant attenuations vs the A\u03b2\u200a25-35-treated group.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>FENM therefore appeared as a potent neuroprotective drug in an AD model, with a superior efficacy compared with Memantine and an absence of direct amnesic effect at higher doses. These results open the possibility to use the compound at more relevant dosages than those actually proposed in Memantine treatment for AD.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ijnp\/pyaa075","type":"journal-article","created":{"date-parts":[[2020,9,24]],"date-time":"2020-09-24T11:47:11Z","timestamp":1600948031000},"page":"142-157","source":"Crossref","is-referenced-by-count":20,"title":["Anti-Amnesic and Neuroprotective Effects of Fluoroethylnormemantine in a Pharmacological Mouse Model of Alzheimer\u2019s Disease"],"prefix":"10.1093","volume":"24","author":[{"given":"Simon","family":"Couly","sequence":"first","affiliation":[{"name":"MMDN, Univ Montpellier, INSERM, EPHE, Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgane","family":"Denus","sequence":"additional","affiliation":[{"name":"MMDN, Univ Montpellier, INSERM, EPHE, Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e9lanie","family":"Bouchet","sequence":"additional","affiliation":[{"name":"MMDN, Univ Montpellier, INSERM, EPHE, Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Rubinstenn","sequence":"additional","affiliation":[{"name":"ReST Therapeutics, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4074-6793","authenticated-orcid":false,"given":"Tangui","family":"Maurice","sequence":"additional","affiliation":[{"name":"MMDN, Univ Montpellier, INSERM, EPHE, Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,9,25]]},"reference":[{"key":"2021021516380034100_CIT0001","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0959-4388(95)80021-2","article-title":"Pharmacology of memory: cholinergic-glutamatergic interactions","volume":"5","author":"Aigner","year":"1995","journal-title":"Curr Opin Neurobiol"},{"key":"2021021516380034100_CIT0002","doi-asserted-by":"crossref","first-page":"129","DOI":"10.3109\/10799899909036640","article-title":"Fluorine-18 radiolabelling, biodistribution studies and preliminary PET evaluation of a new memantine derivative for imaging the NMDA receptor","volume":"19","author":"Ametamey","year":"1999","journal-title":"J Recept Signal Transduct Res"},{"key":"2021021516380034100_CIT0003","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0969-8051(01)00293-1","article-title":"PET studies of 18F-memantine in healthy volunteers","volume":"29","author":"Ametamey","year":"2002","journal-title":"Nucl Med Biol"},{"key":"2021021516380034100_CIT0004","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.neuroscience.2009.08.063","article-title":"Effects of memantine on soluble Alphabeta(25-35)-induced changes in peptidergic and glial cells in Alzheimer\u2019s disease model rat brain regions","volume":"164","author":"Arif","year":"2009","journal-title":"Neuroscience"},{"key":"2021021516380034100_CIT0005","doi-asserted-by":"crossref","first-page":"703","DOI":"10.2478\/s11658-009-0029-x","article-title":"Increased expression of PAD2 after repeated intracerebroventricular infusions of soluble Abeta(25-35) in the Alzheimer\u2019s disease model rat brain: effect of memantine","volume":"14","author":"Arif","year":"2009","journal-title":"Cell Mol Biol Lett"},{"key":"2021021516380034100_CIT0006","doi-asserted-by":"crossref","first-page":"626","DOI":"10.3389\/fnins.2017.00626","article-title":"Cognitive decline in neuronal aging and Alzheimer\u2019s disease: role of NMDA receptors and associated proteins","volume":"11","author":"Avila","year":"2017","journal-title":"Front Neurosci"},{"key":"2021021516380034100_CIT0007","doi-asserted-by":"crossref","first-page":"RRN1291","DOI":"10.1371\/currents.RRN1291","article-title":"Pharmacokinetics of memantine in rats and mice","volume":"3","author":"Beconi","year":"2011","journal-title":"PLoS Curr"},{"key":"2021021516380034100_CIT0008","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1001\/jamaneurol.2013.5847","article-title":"Amyloid-\u03b2 and tau: the trigger and bullet in Alzheimer disease pathogenesis","volume":"71","author":"Bloom","year":"2014","journal-title":"JAMA Neurol"},{"key":"2021021516380034100_CIT0009","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1017\/S135561771700100X","article-title":"Alzheimer\u2019s disease: past, present, and future","volume":"23","author":"Bondi","year":"2017","journal-title":"J Int Neuropsychol Soc"},{"key":"2021021516380034100_CIT0010","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.2105\/AJPH.88.9.1337","article-title":"Projections of Alzheimer\u2019s disease in the United States and the public health impact of delaying disease onset","volume":"88","author":"Brookmeyer","year":"1998","journal-title":"Am J Public Health"},{"key":"2021021516380034100_CIT0011","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/s41583-019-0132-6","article-title":"Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease","volume":"20","author":"Butterfield","year":"2019","journal-title":"Nat Rev Neurosci"},{"key":"2021021516380034100_CIT0012","doi-asserted-by":"crossref","first-page":"7608","DOI":"10.1038\/srep07608","article-title":"Combining two repurposed drugs as a promising approach for Alzheimer\u2019s disease therapy","volume":"5","author":"Chumakov","year":"2015","journal-title":"Sci Rep"},{"key":"2021021516380034100_CIT0013","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.nlm.2018.02.014","article-title":"Topographical memory analyzed in mice using the Hamlet test, a novel complex maze","volume":"149","author":"Crouzier","year":"2018","journal-title":"Neurobiol Learn Mem"},{"key":"2021021516380034100_CIT0014","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1002\/cpmo.43","article-title":"Assessment of topographic memory in mice in a complex environment using the hamlet test","volume":"8","author":"Crouzier","year":"2018","journal-title":"Curr Protoc Mouse Biol"},{"key":"2021021516380034100_CIT0015","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1002\/gps.938","article-title":"The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer\u2019s disease: preclinical evidence","volume":"18","author":"Danysz","year":"2003","journal-title":"Int J Geriatr Psychiatry"},{"key":"2021021516380034100_CIT0016","doi-asserted-by":"crossref","first-page":"11590","DOI":"10.1074\/jbc.M607483200","article-title":"Abeta oligomers induce neuronal oxidative stress through an N-methyl-D-aspartate receptor-dependent mechanism that is blocked by the Alzheimer drug memantine","volume":"282","author":"De Felice","year":"2007","journal-title":"J Biol Chem"},{"key":"2021021516380034100_CIT0017","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1080\/14656566.2016.1215431","article-title":"Pharmacotherapeutic strategies in the treatment of severe Alzheimer\u2019s disease","volume":"17","author":"Deardorff","year":"2016","journal-title":"Expert Opin Pharmacother"},{"key":"2021021516380034100_CIT0018","doi-asserted-by":"crossref","first-page":"3226","DOI":"10.1038\/npp.2008.53","article-title":"Effects of memantine on neuronal structure and conditioned fear in the Tg2576 mouse model of Alzheimer\u2019s disease","volume":"33","author":"Dong","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"2021021516380034100_CIT0019","doi-asserted-by":"crossref","first-page":"319","DOI":"10.3233\/JAD-2007-12405","article-title":"Memantine acts as a cholinergic stimulant in the mouse hippocampus","volume":"12","author":"Drever","year":"2007","journal-title":"J Alzheimers Dis"},{"key":"2021021516380034100_CIT0020","doi-asserted-by":"crossref","first-page":"7327","DOI":"10.1007\/s12035-018-0868-4","article-title":"Peripheral and central effects of memantine in a mixed preclinical mice model of obesity and familial Alzheimer\u2019s disease","volume":"55","author":"Ettcheto","year":"2018","journal-title":"Mol Neurobiol"},{"key":"2021021516380034100_CIT0021","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.3233\/JAD-170672","article-title":"Memantine for the treatment of dementia: a review on its current and future applications","volume":"62","author":"Folch","year":"2018","journal-title":"J Alzheimers Dis"},{"key":"2021021516380034100_CIT0022","doi-asserted-by":"crossref","first-page":"12845","DOI":"10.1074\/jbc.M808759200","article-title":"Propagation of tau misfolding from the outside to the inside of a cell","volume":"284","author":"Frost","year":"2009","journal-title":"J Biol Chem"},{"key":"2021021516380034100_CIT0023","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/nrn2911","article-title":"Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders","volume":"11","author":"Hardingham","year":"2010","journal-title":"Nat Rev Neurosci"},{"key":"2021021516380034100_CIT0024","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1111\/j.1476-5381.2010.00872.x","article-title":"Animal research: reporting in vivo experiments: the ARRIVE guidelines","volume":"160","author":"Kilkenny","year":"2010","journal-title":"Br J Pharmacol"},{"key":"2021021516380034100_CIT0025","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.neuroscience.2006.11.060","article-title":"A neural cell adhesion molecule-derived peptide reduces neuropathological signs and cognitive impairment induced by Abeta25-35","volume":"145","author":"Klementiev","year":"2007","journal-title":"Neuroscience"},{"key":"2021021516380034100_CIT0026","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1038\/npp.2013.70","article-title":"Blockade of Tau hyperphosphorylation and A\u03b2","volume":"38","author":"Lahmy","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"2021021516380034100_CIT0027","doi-asserted-by":"crossref","first-page":"463","DOI":"10.3389\/fncel.2014.00463","article-title":"Mitochondrial protection by the mixed muscarinic\/\u03c31 ligand ANAVEX2-73, a tetrahydrofuran derivative, in A\u03b225-35 peptide-injected mice, a nontransgenic Alzheimer\u2019s disease model","volume":"8","author":"Lahmy","year":"2015","journal-title":"Front Cell Neurosci"},{"key":"2021021516380034100_CIT0028","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s00702-003-0090-y","article-title":"No nerve growth factor response to treatment with memantine in adult rats","volume":"111","author":"Lang","year":"2004","journal-title":"J Neural Transm (Vienna)"},{"key":"2021021516380034100_CIT0029","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.neuroscience.2014.05.011","article-title":"Memantine improves spatial learning and memory impairments by regulating NGF signaling in APP\/PS1 transgenic mice","volume":"273","author":"Liu","year":"2014","journal-title":"Neuroscience"},{"key":"2021021516380034100_CIT0030","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.bbr.2015.09.020","article-title":"Protection by sigma-1 receptor agonists is synergic with donepezil, but not with memantine, in a mouse model of amyloid-induced memory impairments","volume":"296","author":"Maurice","year":"2016","journal-title":"Behav Brain Res"},{"key":"2021021516380034100_CIT0031","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/0006-8993(95)01032-7","article-title":"Amnesia induced in mice by centrally administered beta-amyloid peptides involves cholinergic dysfunction","volume":"706","author":"Maurice","year":"1996","journal-title":"Brain Res"},{"key":"2021021516380034100_CIT0032","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1177\/0269881113494939","article-title":"Intranasal formulation of erythropoietin EPO) showed potent protective activity against amyloid toxicity in the A\u03b2\u200a25\u201335 nontransgenic mouse model of Alzheimer\u2019s disease","volume":"27","author":"Maurice","year":"2013","journal-title":"J Psychopharmacol"},{"key":"2021021516380034100_CIT0033","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.phrs.2019.04.026","article-title":"Neuroprotection in non-transgenic and transgenic mouse models of Alzheimer\u2019s disease by positive modulation of \u03c31 receptors","volume":"144","author":"Maurice","year":"2019","journal-title":"Pharmacol Res"},{"key":"2021021516380034100_CIT0034","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1038\/sj.bjp.0706927","article-title":"The anti-amnesic and neuroprotective effects of donepezil against amyloid beta25-35 peptide-induced toxicity in mice involve an interaction with the sigma1 receptor","volume":"149","author":"Meunier","year":"2006","journal-title":"Br J Pharmacol"},{"key":"2021021516380034100_CIT0035","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ejphar.2012.10.033","article-title":"The \u03b3-secretase inhibitor 2-[(1R)-1-[(4-chlorophenyl)sulfonyl](2,5-difluorophenyl) amino]ethyl-5-fluorobenzenebutanoic acid (BMS-299 897) alleviates A\u03b21-42 seeding and short term memory deficits in the A\u03b225-35 mouse model of Alzheimer\u2019s disease","volume":"698","author":"Meunier","year":"2013","journal-title":"Eur J Pharmacol"},{"key":"2021021516380034100_CIT0036","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1124\/jpet.104.071027","article-title":"Memantine improves spatial learning in a transgenic mouse model of Alzheimer\u2019s disease","volume":"311","author":"Minkeviciene","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"key":"2021021516380034100_CIT0037","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0014-2999(95)00682-6","article-title":"Learning deficits induced by chronic intraventricular infusion of quinolinic acid\u2013protection by MK-801 and memantine","volume":"296","author":"Misztal","year":"1996","journal-title":"Eur J Pharmacol"},{"key":"2021021516380034100_CIT0038","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.neuropharm.2013.08.013","article-title":"Dysfunctional synapse in Alzheimer\u2019s disease - a focus on NMDA receptors","volume":"76 Pt A","author":"Mota","year":"2014","journal-title":"Neuropharmacology"},{"key":"2021021516380034100_CIT0039","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ejphar.2006.07.049","article-title":"Cognitive dysfunction induced by sequential injection of amyloid-beta and ibotenate into the bilateral hippocampus; protection by memantine and MK-801","volume":"548","author":"Nakamura","year":"2006","journal-title":"Eur J Pharmacol"},{"key":"2021021516380034100_CIT0040","doi-asserted-by":"crossref","first-page":"539","DOI":"10.2165\/11591860-000000000-00000","article-title":"Combination therapy for Alzheimer\u2019s disease","volume":"28","author":"Patel","year":"2011","journal-title":"Drugs Aging"},{"key":"2021021516380034100_CIT0041","volume-title":"The mouse brain in stereotaxic coordinates","author":"Paxinos","year":"2004"},{"key":"2021021516380034100_CIT0042","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1523\/JNEUROSCI.13-04-01676.1993","article-title":"Neurodegeneration induced by beta-amyloid peptides in vitro: the role of peptide assembly state","volume":"13","author":"Pike","year":"1993","journal-title":"J Neurosci"},{"key":"2021021516380034100_CIT0043","doi-asserted-by":"crossref","first-page":"231","DOI":"10.3233\/JAD-160500","article-title":"An intranasal formulation of erythropoietin (Neuro-EPO) prevents memory deficits and amyloid toxicity in the APPSwe transgenic mouse model of Alzheimer\u2019s disease","volume":"55","author":"Rodr\u00edguez Cruz","year":"2017","journal-title":"J Alzheimers Dis"},{"key":"2021021516380034100_CIT0044","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/j.neuroscience.2006.08.017","article-title":"Memantine protects against LPS-induced neuroinflammation, restores behaviorally-induced gene expression and spatial learning in the rat","volume":"142","author":"Rosi","year":"2006","journal-title":"Neuroscience"},{"key":"2021021516380034100_CIT0045","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.nucmedbio.2015.04.001","article-title":"Radiolabeling of [18F]-fluoroethylnormemantine and initial in vivo evaluation of this innovative PET tracer for imaging the PCP sites of NMDA receptors","volume":"42","author":"Salabert","year":"2015","journal-title":"Nucl Med Biol"},{"key":"2021021516380034100_CIT0046","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.nucmedbio.2017.12.003","article-title":"Evaluation of [18F]FNM biodistribution and dosimetry based on whole-body PET imaging of rats","volume":"59","author":"Salabert","year":"2018","journal-title":"Nucl Med Biol"},{"key":"2021021516380034100_CIT0047","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/j.1365-2125.2011.04134.x","article-title":"New pharmacological strategies for treatment of Alzheimer\u2019s disease: focus on disease modifying drugs","volume":"73","author":"Salomone","year":"2012","journal-title":"Br J Clin Pharmacol"},{"key":"2021021516380034100_CIT0048","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S0969-8051(98)00003-1","article-title":"Electrophysiological study, biodistribution in mice, and preliminary PET evaluation in a rhesus monkey of 1-amino-3-[18F]fluoromethyl-5-methyl-adamantane (18F-MEM): a potential radioligand for mapping the NMDA-receptor complex","volume":"25","author":"Samnick","year":"1998","journal-title":"Nucl Med Biol"},{"key":"2021021516380034100_CIT0049","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/0896-6273(91)90052-2","article-title":"The molecular pathology of Alzheimer\u2019s disease","volume":"6","author":"Selkoe","year":"1991","journal-title":"Neuron"},{"key":"2021021516380034100_CIT0050","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/ncb1104-1054","article-title":"Cell biology of protein misfolding: the examples of Alzheimer\u2019s and Parkinson\u2019s diseases","volume":"6","author":"Selkoe","year":"2004","journal-title":"Nat Cell Biol"},{"key":"2021021516380034100_CIT0051","doi-asserted-by":"crossref","first-page":"943","DOI":"10.3389\/fphar.2019.00943","article-title":"The concentration of memantine in the cerebrospinal fluid of Alzheimer\u2019s disease patients and its consequence to oxidative stress biomarkers","volume":"10","author":"Valis","year":"2019","journal-title":"Front Pharmacol"},{"key":"2021021516380034100_CIT0052","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s00213-004-2132-z","article-title":"Symptomatic effect of donepezil, rivastigmine, galantamine and memantine on cognitive deficits in the APP23 model","volume":"180","author":"Van Dam","year":"2005","journal-title":"Psychopharmacology (Berl)"},{"key":"2021021516380034100_CIT0053","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.euroneuro.2005.06.005","article-title":"Cognitive evaluation of disease-modifying efficacy of galantamine and memantine in the APP23 model","volume":"16","author":"Van Dam","year":"2006","journal-title":"Eur Neuropsychopharmacol"},{"key":"2021021516380034100_CIT0054","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1038\/npp.2008.212","article-title":"Antiamnesic and neuroprotective effects of the aminotetrahydrofuran derivative ANAVEX1-41 against amyloid beta(25-35)-induced toxicity in mice","volume":"34","author":"Villard","year":"2009","journal-title":"Neuropsychopharmacology"},{"key":"2021021516380034100_CIT0055","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1177\/0269881110379286","article-title":"Anti-amnesic and neuroprotective potentials of the mixed muscarinic receptor\/sigma1 (\u03c3\u200a1) ligand ANAVEX2-73, a novel aminotetrahydrofuran derivative","volume":"25","author":"Villard","year":"2011","journal-title":"J Psychopharmacol"},{"key":"2021021516380034100_CIT0056","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.3233\/JAD-160763","article-title":"Role of glutamate and NMDA receptors in Alzheimer\u2019s disease","volume":"57","author":"Wang","year":"2017","journal-title":"J Alzheimers Dis"},{"key":"2021021516380034100_CIT0057","doi-asserted-by":"crossref","first-page":"e0145441","DOI":"10.1371\/journal.pone.0145441","article-title":"Memantine attenuates Alzheimer\u2019s disease-like pathology and cognitive impairment","volume":"10","author":"Wang","year":"2015","journal-title":"Plos One"},{"key":"2021021516380034100_CIT0058","doi-asserted-by":"crossref","first-page":"11246","DOI":"10.1523\/JNEUROSCI.2488-10.2010","article-title":"Memantine preferentially blocks extrasynaptic over synaptic NMDA receptor currents in hippocampal autapses","volume":"30","author":"Xia","year":"2010","journal-title":"J Neurosci"},{"key":"2021021516380034100_CIT0059","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/0014-2999(95)00716-4","article-title":"Infusion of (+) -MK-801 and memantine \u2013 contrasting effects on radial maze learning in rats with entorhinal cortex lesion","volume":"296","author":"Zajaczkowski","year":"1996","journal-title":"Eur J Pharmacol"}],"container-title":["International Journal of Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ijnp\/advance-article-pdf\/doi\/10.1093\/ijnp\/pyaa075\/33882486\/pyaa075.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ijnp\/article-pdf\/24\/2\/142\/36267983\/pyaa075.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ijnp\/article-pdf\/24\/2\/142\/36267983\/pyaa075.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,16]],"date-time":"2021-02-16T03:44:17Z","timestamp":1613447057000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ijnp\/article\/24\/2\/142\/5911815"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,25]]},"references-count":59,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,9,25]]},"published-print":{"date-parts":[[2021,2,15]]}},"URL":"https:\/\/doi.org\/10.1093\/ijnp\/pyaa075","relation":{},"ISSN":["1461-1457","1469-5111"],"issn-type":[{"value":"1461-1457","type":"print"},{"value":"1469-5111","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,2,1]]},"published":{"date-parts":[[2020,9,25]]}}}